These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 17059380

  • 1. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
    Mastroianni CM, d'Ettorre G, Vullo V.
    Expert Opin Pharmacother; 2006 Nov; 7(16):2233-41. PubMed ID: 17059380
    [Abstract] [Full Text] [Related]

  • 2. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M, Staszewski S, Doerr HW.
    Antivir Ther; 2007 Nov; 12(5):695-703. PubMed ID: 17713153
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
    d'Ettorre G, Zaffiri L, Ceccarelli G, Andreotti M, Massetti AP, Vella S, Mastroianni CM, Vullo V.
    HIV Clin Trials; 2007 Nov; 8(3):182-8. PubMed ID: 17621465
    [Abstract] [Full Text] [Related]

  • 7. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR.
    J Infect Dis; 2005 Dec 01; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract] [Full Text] [Related]

  • 8. Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
    Haskelberg H, Pocock N, Amin J, Ebeling PR, Emery S, Carr A, STEAL study investigators, Allworth A.
    PLoS One; 2014 Dec 01; 9(4):e94858. PubMed ID: 24722774
    [Abstract] [Full Text] [Related]

  • 9. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G, Higgs C, Teague A, Mandalia S, Nelson M, Johnson M, Fisher M, Gazzard B.
    Antivir Ther; 2006 Dec 01; 11(1):73-8. PubMed ID: 16518962
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
    Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R, COL40263 study.
    J Antimicrob Chemother; 2010 Feb 01; 65(2):307-15. PubMed ID: 20008905
    [Abstract] [Full Text] [Related]

  • 14. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2010 Oct 06; (10):CD008740. PubMed ID: 20927777
    [Abstract] [Full Text] [Related]

  • 15. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
    Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.
    Antivir Ther; 2007 Oct 06; 12(1):25-30. PubMed ID: 17503744
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
    Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A, UCSC cohort, MASTER cohort, ARCA cohort.
    Infection; 2009 Oct 06; 37(5):438-44. PubMed ID: 19669091
    [Abstract] [Full Text] [Related]

  • 17. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS, ESS30009 Study.
    J Infect Dis; 2005 Dec 01; 192(11):1921-30. PubMed ID: 16267763
    [Abstract] [Full Text] [Related]

  • 18. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.
    Latham V, Stebbing J, Mandalia S, Michailidis C, Davies E, Bower M, Gazzard B, Nelson M.
    J Antimicrob Chemother; 2005 Jul 01; 56(1):186-9. PubMed ID: 15911551
    [Abstract] [Full Text] [Related]

  • 19. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
    Kagan RM, Lee TS, Ross L, Lloyd RM, Lewinski MA, Potts SJ.
    Antiviral Res; 2007 Sep 01; 75(3):210-8. PubMed ID: 17442410
    [Abstract] [Full Text] [Related]

  • 20. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A, Mandalia S, Pillay D, Gazzard B, Pozniak A.
    AIDS; 2002 Oct 18; 16(15):2087-9. PubMed ID: 12370512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.